Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study

Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study

BackgroundAlthough immune checkpoint inhibitors (ICIs) have become the frontline treatment option for patients with various advanced cancers due to improved survival, they can be associated with a spectrum of cutaneous immune-related adverse events (cirAEs). However, little is known regarding the oc...

Full description

Bibliographic Details
Main Authors:	Athitaya Luangnara, Salin Kiratikanon, Thanika Ketpueak, Thatthan Suksombooncharoen, Chaiyut Charoentum, Busyamas Chewaskulyong, Napatra Tovanabutra, Siri Chiewchanvit, Surapon Nochaiwong, Mati Chuamanochan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Immunology
Subjects:	anti-programmed cell death-1 anti-programmed cell death ligand-1 cutaneous immune-related adverse event cytotoxic T-lymphocyte antigen-4 inhibitors immune checkpoint inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.965550/full

Similar Items

Clinical Outcomes, Patient-Reported Outcomes, and Economic Burden for Thai People Living with Chronic Urticaria (CORE-CU) in routine practice: A study protocol for a monocentric prospective longitudinal study.
by: Mati Chuamanochan, et al.
Published: (2023-01-01)

Evidence Gaps in Clinical Trials of Pharmacologic Treatment for H1-Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Future Perspectives
by: Surapon Nochaiwong, et al.
Published: (2022-10-01)

Pythiosis presenting with chronic swelling and painful subcutaneous lesion at right deltoid
by: Athitaya Luangnara, et al.
Published: (2023-01-01)

Comparative immunohistochemical analysis of inflammatory cytokines in distinct subtypes of Sweet syndrome
by: Panjit Chieosilapatham, et al.
Published: (2024-03-01)

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients
by: Busyamas Chewaskulyong, et al.
Published: (2024-01-01)

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.
by: Busyamas Chewaskulyong, et al.
Published: (2024-01-01)

Pharmacological interventions for hidradenitis suppurativa: a protocol for systematic review and network meta-analysis of randomised trials and non-randomised studies
by: Phichayut Phinyo, et al.
Published: (2022-09-01)

Incidence of postpartum infections and outcomes associated with antibiotic prophylaxis after normal vaginal birth
by: Thitipong Sirilak, et al.
Published: (2022-09-01)

Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis
by: Pajaree Mongkhon, et al.
Published: (2023-12-01)

Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials
by: Nuttaya Wachiraphansakul, et al.
Published: (2024-01-01)

Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials.
by: Nuttaya Wachiraphansakul, et al.
Published: (2024-01-01)

Association between oral health conditions and the risk of major noncommunicable diseases: A protocol for systematic review and meta-analysis
by: Natchanon Promruck, et al.
Published: (2024-10-01)

Temporal trend in quality indicators of diabetes care performance among persons with type 2 diabetes in primary care practice: a serial cross-sectional analytical study, 2013/14 to 2021/22
by: Ratanaporn Awiphan, et al.
Published: (2024-10-01)

Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial
by: Kajohnsak Noppakun, et al.
Published: (2021-01-01)

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
by: Ryotaro Ohkuma, et al.
Published: (2021-12-01)

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
by: Wenjuan Tian, et al.
Published: (2024-08-01)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
by: Cheng S, et al.
Published: (2023-04-01)

Genetic association of beta-lactams-induced hypersensitivity reactions: A systematic review of genome-wide evidence and meta-analysis of candidate genes
by: Lalita Lumkul, M.Sc, et al.
Published: (2023-09-01)

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
by: Ming-Yan Shi, et al.
Published: (2023-01-01)

Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody
by: Makiko Sasaki, et al.
Published: (2023-03-01)

Transcultural adaptation and psychometric validation of the Thai-Brief Resilient Coping Scale: a cross-sectional study during the coronavirus disease 2019 pandemic in Thailand
by: Surapon Nochaiwong, et al.
Published: (2022-12-01)

Characteristics and clinical outcomes of checkpoint inhibitor-associated pneumonia in cancer patients: a retrospective analysis of 1 084 cases
by: YANG Yan, et al.
Published: (2024-08-01)

Identification of Novel Aryl Carboxamide Derivatives as Death-Associated Protein Kinase 1 (DAPK1) Inhibitors with Anti-Proliferative Activities: Design, Synthesis, In Vitro, and In Silico Biological Studies
by: Ahmed Elkamhawy, et al.
Published: (2022-08-01)

Sporothrix schenckii sensu stricto related to zoonotic transmission in Thailand
by: Panjit Chieosilapatham, et al.
Published: (2023-09-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial
by: Tomoaki Sonoda, et al.
Published: (2023-06-01)

Cordycepin Augments the Efficacy of Anti-PD1 against Colon Cancer
by: Wen-Kuei Chang, et al.
Published: (2024-07-01)

The role of ferroptosis in neurodegenerative diseases
by: Yifan Fei, et al.
Published: (2024-10-01)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysisResearch in context
by: Andrea York Tiang Teo, et al.
Published: (2024-11-01)

Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study
by: Boucheron T, et al.
Published: (2025-03-01)

Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer
by: Yuichiro Iwamoto, et al.
Published: (2023-01-01)

Circadian clock regulates immune checkpoint inhibitor efficacy
by: Yining Niu, et al.
Published: (2025-02-01)

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
by: Aung Naing, et al.
Published: (2025-01-01)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
by: Xiuju Liang, et al.
Published: (2019-12-01)

In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy
by: Jiehan Li, et al.
Published: (2022-03-01)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
by: Chieh-Hsun Chen, et al.
Published: (2022-04-01)

Survival rates in comprehensive conservative care compared to dialysis therapy in elderly end-stage kidney disease patients: a propensity score analysis
by: Kajohnsak Noppakun, et al.
Published: (2024-12-01)

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
by: Shibo Huang, et al.
Published: (2024-01-01)

Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs)
by: Yi-Xiu Long, et al.
Published: (2022-01-01)